Companion Spine Announces FDA Premarket Approval (“PMA”) of the DIAM™ Spinal Stabilization System for the Treatment of Degenerative Disc Disease (“DDD”) DIAM™ Spinal Stabilization System is the first ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--July 10, 2006--Medtronic, Inc. (NYSE:MDT) announced today that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) to the ...

Companion Spine SAS received premarket approval from the U.S. FDA for its DIAM spinal stabilization system, for treatment of degenerative disc disease. The approval comes as the company recently ...

The Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee of the FDA voted when it met on February 19 against three questions related to a premarket application for ...

SAN FRANCISCO (MarketWatch) -- Medtronic Inc. said Wednesday the Food and Drug Administration has granted an investigational device exemption to the DIAM spinal stabilization system for use in a ...

MÉRIGNAC, France, December 15, 2025--(BUSINESS WIRE)--Companion Spine, the French-American specialist in surgeon innovated spine implant surgery, announced that the U.S. Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . The Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee of the FDA voted when ...

DIAM™ Spinal Stabilization System is the first posterior motion-preserving device approved in the U.S. for the treatment of moderate to severe primary low back pain secondary to DDD at a single lumbar ...

DIAM Spinal Stabilization System is the first posterior motion-preserving device approved in the U.S. for the treatment of moderate to severe primary low back pain A breakthrough treatment addressing ...